- Home
- DOYU vs GNLX Comparison
DOYU vs GNLX Comparison
Compare DOYU & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- GNLX
- Stock Information
- Founded
- DOYU 2014
- GNLX 2001
- Country
- DOYU China
- GNLX United States
- Employees
- DOYU N/A
- GNLX N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- DOYU Technology
- GNLX Health Care
- Exchange
- DOYU Nasdaq
- GNLX Nasdaq
- Market Cap
- DOYU 206.3M
- GNLX 184.4M
- IPO Year
- DOYU 2019
- GNLX 2023
- Fundamental
- Price
- DOYU $6.94
- GNLX $2.96
- Analyst Decision
- DOYU Sell
- GNLX Strong Buy
- Analyst Count
- DOYU 3
- GNLX 4
- Target Price
- DOYU $10.33
- GNLX $17.75
- AVG Volume (30 Days)
- DOYU 63.4K
- GNLX 138.3K
- Earning Date
- DOYU 06-04-2025
- GNLX 05-06-2025
- Dividend Yield
- DOYU 280.00%
- GNLX N/A
- EPS Growth
- DOYU N/A
- GNLX N/A
- EPS
- DOYU N/A
- GNLX N/A
- Revenue
- DOYU $585,116,720.00
- GNLX N/A
- Revenue This Year
- DOYU N/A
- GNLX N/A
- Revenue Next Year
- DOYU N/A
- GNLX N/A
- P/E Ratio
- DOYU N/A
- GNLX N/A
- Revenue Growth
- DOYU N/A
- GNLX N/A
- 52 Week Low
- DOYU $5.68
- GNLX $1.60
- 52 Week High
- DOYU $20.17
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- DOYU 44.11
- GNLX 54.28
- Support Level
- DOYU $7.52
- GNLX $2.26
- Resistance Level
- DOYU $7.67
- GNLX $3.06
- Average True Range (ATR)
- DOYU 0.37
- GNLX 0.31
- MACD
- DOYU 0.09
- GNLX 0.04
- Stochastic Oscillator
- DOYU 34.81
- GNLX 78.42
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.